Treatment with the targeted therapy Venclexta (venetoclax) in combination with chemotherapy led to disease remission for most people with hard-to-treat…
Articles by Marisa Wexler, MS
The experimental therapy 177Lu-edotreotide outperformed the approved treatment everolimus in prolonging progression-free survival in people with pancreatic neuroendocrine tumors…
A committee of the European Medicines Agency (EMA) has recommended the approval of Ipsen‘s tovorafenib for the treatment of…
A low dose of alnodesertib added to standard chemotherapy significantly reduced the likelihood of disease progression among people with platinum-resistant…
Early results from the Phase 2/3 MIRACLE clinical trial suggest that the experimental chemotherapy drug annamycin may offer meaningful benefit…
A new blood test powered by artificial intelligence (AI) could offer a life-saving head start for patients at high risk…
An “immuno-gene” therapy that turns a virus into a cancer-fighting agent has received a fast-track designation from the U.S. Food…
People in the U.S. with certain gynecological cancers that are resistant to first-line chemotherapies now have a new treatment option:…
The U.S. Food and Drug Administration (FDA) is reviewing an application from Bristol Myers Squibb (BMS) seeking approval of…
The U.S. Food and Drug Administration (FDA) has approved the combination of two oral therapies, Venclexta (venetoclax) and Calquence (acalabrutinib),…